International patents law and public health: Revisiting the TRIPS compulsory licensing regime and the Doha Paragraph-6 System

The article presents a critique of the Doha Paragraph 6 System and challenges its effectualness as a real panacea to the global access to medicines conundrum. The article posits that without the ability to manufacture pharmaceuticals locally, the TRIPS compulsory licensing regime in the long term offers no significant advantage to the world’s most vulnerable populations.